Related Experiment Video

Updated: Jul 19, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Investigating mammalian target of rapamycin inhibitors for their anticancer properties

Piotr Smolewski1

  • 1Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Ciolkowskiego 2, 93-510 Lodz, Poland. piotr_smolewski@wp.pl

Expert Opinion on Investigational Drugs
|September 23, 2006
PubMed

Insights

The mammalian target of rapamycin (mTOR) pathway regulates cell growth and is often abnormal in cancers. Inhibitors of mTOR show promise as anticancer drugs, especially when combined with other treatments.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • The mammalian target of rapamycin (mTOR) is a crucial regulator of cell growth and proliferation within the PI3K/Akt signaling pathway.
  • Dysregulation of the mTOR pathway is implicated in the development of various human cancers.
  • mTOR's central role makes it a significant target for novel anticancer drug development.

Purpose of the Study:

  • To investigate the role of the mTOR pathway in cell growth and cancer.
  • To evaluate the efficacy of mTOR inhibitors as potential anticancer agents.
  • To explore the synergistic potential of mTOR inhibitors with other therapeutic modalities.

Main Methods:

  • Review of existing literature on mTOR signaling and its role in malignancies.
  • Analysis of data from clinical trials involving mTOR inhibitors (e.g., rapamycin, CCI-779, RAD-001, AP-23573).
  • Examination of studies investigating combination therapies involving mTOR inhibitors.

Main Results:

  • mTOR pathway activation is frequently observed in human cancers.
  • Specific mTOR inhibitors have demonstrated activity in Phase I/II clinical trials for solid tumors and hematological malignancies.
  • mTOR inhibitors exhibit synergistic effects when combined with certain chemotherapeutics and biological agents.

Conclusions:

  • Targeting the mTOR pathway with specific inhibitors is a viable anticancer strategy.
  • Combination therapies involving mTOR inhibitors represent a promising avenue for future antitumour treatment strategies.
  • Further clinical investigation into mTOR-targeted therapies is warranted for various malignancies.

More Related Videos

Development and Application of Rapamycin-regulated Tyrosine Phosphatases06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...